Please login to the form below

Not currently logged in
Email:
Password:

QVA149

This page shows the latest QVA149 news and features for those working in and with pharma, biotech and healthcare.

Boehringer bags FDA approval for Spiriva-based combo

Boehringer bags FDA approval for Spiriva-based combo

Competition is only expected to increase further in COPD. For example, Novartis is due to enter the US LAMA/LABA category shortly with its QVA149 (glycopyrronium bromide/indacaterol) product, which is

Latest news

  • Novartis files COPD combo in US Novartis files COPD combo in US

    QVA149 is already on the market in the EU under the Ultibro brand name having been approved in 2013 as the first LABA/LAMA for COPD. ... Novartis is hoping new data from its pivotal clinical trial programmes will help position QVA149 in the market.

  • FDA approves Boehringer COPD spray Striverdi Respimat FDA approves Boehringer COPD spray Striverdi Respimat

    But there is a lot of potential competition in COPD at present, including Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) and GSK and Theravance's Anoro (umeclidinium bromide and vilanterol).

  • Novartis, Boehringer stake claims to combination COPD market Novartis, Boehringer stake claims to combination COPD market

    Ultibro (formerly QVA149) was the first LAMA/LABA to be approved for marketing in the EU, while rival product Anoro (umeclidinium bromide and vilanterol) from GlaxoSmithKline was the first drug in

  • Novartis' combo COPD inhaler cleared in EU Novartis' combo COPD inhaler cleared in EU

    COPD). Ultibro (formerly QVA149) combines the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide with the long-acting beta agonist (LABA) indacaterol, which are already approved as monotherapies in the EU as

  • FDA queries safety of GSK's Anoro for COPD FDA queries safety of GSK's Anoro for COPD

    GSK will find the COPD market increasing competitive, however, with a panoply of other new COPD combinations coming through the pipeline, including Boehringer Ingelheim/Pfizer's olodaterol/tiotropium, Novartis' QVA149 (glycopyrronium

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics